Form 4 for ALT Altimmune, Inc.
Accepted 2023-02-02 00:00:00 ET · period of report 2023-01-31 · accession 0001104659-23-009975 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-02 | 2023-01-31 | ALT | Roberts M Scot | CSO | A - Grant | $10.21 | +1,436 | 10.5K | +16% | +$14.7K |
| D | 2023-02-02 | 2023-02-01 | ALT | Roberts M Scot | CSO | M - OptEx | $0.00 | +6,166 | 16.6K | +59% | $0 |
| D | 2023-02-02 | 2023-02-01 | ALT | Roberts M Scot | CSO | F - Tax | $13.78 | -2,183 | 14.5K | -13% | -$30.1K |
| D | 2023-02-02 | 2023-02-01 | ALT | Roberts M Scot | CSO | M - OptEx | $0.00 | -6,166 | 12.3K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.0001 | 2023-01-31 | A | A | 1,436 | $10.21 | 10,473 | D | — | — | (F2) In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2022. |
| 2 | Common | Common Stock, par value $0.0001 | 2023-02-01 | M | A | 6,166 | $0.00 | 16,639 | D | — | — | (F3) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. |
| 3 | Common | Common Stock, par value $0.0001 | 2023-02-01 | F | D | 2,183 | $13.78 | 14,456 | D | — | — | |
| 4 | Derivative | Restricted Stock Units | 2023-02-01 | M | D | 6,166 | $0.00 | 12,332 | D | — · — to — | 6,166 Common Stock, par value $0.0001 | (F3) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. (F5) The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. |